000			03380nam\a2200313\a\4500
001			57917
005			20260728112029.0
008			260728s2017 gw |||| o |||| 0|eng
020			_a9783319404004
040			_aDLC _beng _epn _erda _cDLC _dBD-DhIUB
082	0	4	_a353.998 _223 _bP5361
245	0	0	_aPharmacovigilance : _bCritique and Ways Forward / _cedited by I. Ralph Edwards, Marie Lindquist.
250			_a1st ed. 2017.
260			_aSwitzerland: _bSpringer International publishing AG, _c2017
300			_a1 online resource (XXXI, 205 pages 16 illustrations, 3 illustrations in color.)
505	0		_a1. How to learn Pharmacovigilance, now and in the Future -- 2. Lost in Regulation -- 3. What is the Future of Pharmacovigilance and how can we Make it as Good as Possible? -- 4. Some Other Ideas About the Future of Pharmacovigilance -- 5. Best Safety Practices now and in the Future -- 6. Is There a Benefit from the Medical Literature Monitoring Service of the EMA? -- 7. The Unified Drug Safety-Clinical Database -- 8. Behind the Scenes - 'Silent Factors' Influencing Pharmacovigilance Practice and Decisions -- 9. Shaking up Culture and Communication in PV [V6] -- 10. Broadening the Scope of Pharmacovigilance -- 11. Effective Treatment Matters: Revitalizing Pharmacoviglance -- 12. There are More Weber-Effects -- 13. Herbal and Traditional Medicines, Now and Future -- 14. The Concept of 'Health' -- 15. Impact of Referral Procedures on the Interaction of RMP and PSUR -- 16. Other Sources of Information for Monitoring Drug Safety: Now and in the Future -- 17. Ecopharmacovigilance.
520			_aWritten by experienced authors, this book offers expert personal views on what the current problems in pharmacovigilance are and how they should be solved. This book stems from thoughts and ideas discussed in a series of meetings of the International Society of Pharmacovigilance (ISoP), where concerns were raised that the current pharmacovigilance system is not delivering optimally to improve therapeutics in clinical practice. Pharmacovigilance of the future must be an active and integral part of health care delivery, and focus more on science and practices that support health professionals and patients in day-to-day care situations. To achieve this, a dynamic and sustainable development of vigilance must take precedence over the current excessive preoccupations with data processing and regulations; all aspects of medicines use and their effects need to be considered; and all stakeholders must be involved and engaged in an open and constructive debate. The work is essential reading for anyone who has an interest in safer use of medicines. It is intended to be equally challenging and rewarding, and sets out to stimulate a continuous debate on how pharmacovigilance can better meet the needs of health professionals and patients to achieve the aim of wise therapeutic decision making.
526			_aSLAS _bphr _lPHAR
541			_aOmni concept
650		0	_aPharmacy.
650	1	4	_aDrug Safety and Pharmacovigilance.
700	1		_aEdwards, I. Ralph. _eeditor.
700	1		_aLindquist, Marie. _eeditor.
776	0	8	_iPrint version: _tPharmacovigilance _z9783319403991 _w(DLC) 2016957290
776	0	8	_iPrinted edition: _z9783319403991
776	0	8	_iPrinted edition: _z9783319404011
776	0	8	_iPrinted edition: _z9783319820934
942			_2ddc _cBK
999			_c57917 _d58091